In the mid-1970s, a cancer diagnosis came with roughly a coin-flip chance of survival. The 5-year survival rate sat at 49%. That meant that more than half of the people diagnosed with cancer didn’t make it past the 5-year mark. According to the American Cancer Society’s Cancer Statistics 2026 report, for the first time in recorded history, 70% of Americans diagnosed with cancer are now alive 5 years later. The most dramatic improvements came precisely where they were needed most: the deadliest cancers, the ones caught late, and the ones that once felt like a guaranteed death sentence. So what actually changed inside the treatment room? It’s actually been driven by progress over the past 30 years, particularly in terms of more targeted treatment and immunotherapy. Not only is immunotherapy working extremely well, but it's less toxic, so people can stay on their cancer treatment longer and thus live longer. For decades, cancer treatment meant chemotherapy, a blunt instrument that targeted rapidly dividing cells without distinguishing between cancerous ones and healthy ones. Patients survived the cancer but endured brutal side effects that often cut short their ability to continue treatment. Immunotherapy changed the equation entirely. Rather than poisoning the cancer directly, immunotherapy trains the body’s own immune system to recognize and destroy cancer cells. According to the American Institute for Cancer Research, 43% of previously untreated advanced melanoma patients that were given a combination of immunotherapy drugs were still alive after 10 years. There is a deeply embedded cultural narrative that cancer is essentially still a death sentence, but that narrative is now badly out of date.
